CLAIMS:

1. Use of neratinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a HER-2-positive solid tumor, wherein the medicament further comprises capecitabine.

2. The use according to claim 1, wherein the solid tumor is non-small cell lung cancer, prostate, colorectal, breast or ovarian cancer.

3. The use according to claim 2, wherein the breast cancer is HER-2 overexpressed metastatic or locally advanced breast cancer.

4. The use according to claim 1, wherein one or both of the active components of the medicament is provided in a sub-therapeutically effective amount.

5. The use according to any one of claims 1-4, wherein the capecitabine is formulated for administration in an amount of 1250 mg to 3000 mg, 750 mg to 2000 mg, 900 mg to 1800 mg, or 1250 mg to 1450 mg daily.

6. The use according to any one of claims 1-5, wherein the capecitabine is formulated for administration at least once over a period of 21 days.

7. The use according to claim 6, wherein the capecitabine is formulated for continued administration for 3 to 6 cycles.

8. The use according to any one of claims 1-4, wherein the neratinib or pharmaceutically acceptable salt thereof is formulated for administration at a dose range of 20 to 240 mg daily.

9. The use according to claim 8, wherein the neratinib or pharmaceutically acceptable salt thereof is formulated for administration in an amount of at least about 40 mg.

10. The use according to claim 9, wherein the neratinib or pharmaceutically acceptable salt thereof is formulated for administration in an amount of at least about 120 mg.

11. The use according to claim 10, wherein the neratinib or pharmaceutically acceptable salt thereof is formulated for administration in an amount of at least about 240 mg.

12. The use according to claim 1, wherein the neratinib or pharmaceutically acceptable salt thereof is formulated for daily administration.

13. The use according to claim 1, wherein the neratinib or pharmaceutically acceptable salt thereof is formulated for at least once daily administration.

14. The use according to claim 1, wherein the neratinib or pharmaceutically acceptable salt thereof is formulated for at least two continuous weeks administration.

15. The use according to claim 1, wherein the solid tumor is breast cancer and wherein one cycle of the treatment comprises 21 days and the treatment comprises:

(a) oral administration of at least one unit dose of the neratinib or pharmaceutically acceptable salt thereof daily starting on day 1 of said cycle; and

(b) oral administration of at least one unit dose of capecitabine on days 1 to 14 of said cycle.

16. Use of a pharmaceutical pack said pharmaceutical pack consisting of:

(a) at least one unit dose of capecitabine; and

(b) at least one unit dose of neratinib or a pharmaceutically acceptable salt thereof,

in the manufacture of a medicament for treating a HER-2-positive solid tumor.